Replies to post #251774 on Biotech Values

[jbog]

Your post from Feb lead me to believe that Daxi is being used in the CD field. Foley's comments below wouldn't have been the result of a trial.

RVNC—Cervical-dystonia discussion—and market-share ramifications—from 4Q23 CC:

On today’s CC Foley disclosed that RVNC is seeing excellent results from injectors who are giving CD patients half as much active toxin as these injectors typically give the same CD patients when they are treated with Botox. (I.e. the injectors are dosing 1:1 in labeled numerical units rather than 2:1). On first hearing this I found it astonishing, but after thinking it over I realized that it makes perfect sense.